Coronary Heart Disease: Implementation Of Imaging Modalities To Optimize Cost-Effectiveness

preprint OA: closed
View at publisher
AI-generated summary by claude@2026-07, 2026-07-14

This review examines the cost-effectiveness of different imaging modalities for coronary heart disease diagnosis, finding that a multimodality approach offers the best clinical and economic performance.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Background: /Objectives: cardiovascular diseases remain the most significant health and economic challenge in Stable Economy Countries. Myocardial perfusion imaging (MPI) using single-photon emission computed tomography (SPECT) or positron emission to-mography (PET) has long been a cornerstone in the diagnosis and management of coro-nary heart disease (CHD). However, in an era of increasing healthcare costs and emergence of new imaging technologies, the cost-effectiveness of nuclear cardiology has come under critical evaluation and the implementation of different modalities of imaging need to be considerd. Methods: this review describe the characteristic of the two principal methods of economic analysis used to measure health benefits and presents an overview of the rele-vant trials published so far on the cost-effectiveness of different imaging modalities in the evaluation of CHD. Results: due to the great variability of data conditioned by facility availability, expertise, setting of patients (inpatients vs outpatients), healthcare systems, reimbursement, systems based on insurance company a definite cost effectiveness analysis cannot be obtain. Conclusions: a multimodalities approach seems to offer better perfor-mances both in clinical and in the economical analysis.

My notes (saved in your browser only)

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2025) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.

Source provenance

europepmc
last seen: 2026-05-20T01:45:00.602351+00:00